Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions ( (EBS) ) has shared an announcement.
On September 5, 2025, Emergent BioSolutions received a $56 million contract modification from the U.S. Department of Health and Human Services to supply ACAM2000, a smallpox and mpox vaccine, under an existing 10-year contract. This modification underscores the ongoing collaboration between Emergent and the U.S. government to prioritize public health preparedness, with deliveries expected to begin in September 2025, contributing to projected sales of over $120 million for the year.
The most recent analyst rating on (EBS) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.
Emergent Biosolutions’ overall stock score is driven by positive corporate events and a favorable valuation, suggesting potential for growth. However, financial performance challenges and mixed technical indicators temper the outlook. The earnings call provided a positive sentiment with increased guidance, but ongoing profitability issues remain a concern.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions Inc. operates in the biopharmaceutical industry, focusing on developing and manufacturing vaccines and therapeutics for public health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies. The company is committed to providing protective and life-saving solutions to enhance public health preparedness.
Average Trading Volume: 1,299,487
Technical Sentiment Signal: Buy
Current Market Cap: $425.2M
Learn more about EBS stock on TipRanks’ Stock Analysis page.